SCHEMBL4490477

SCHEMBL4490477

Cc1[nH]c(C)c(-c2ccc(-c3ccccc3)nc2)c(=O)c1Br

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.48
HPGDS O60760 2/20 0.43
DHODH Q02127 2/20 0.40
LDHA P00338 2/20 0.38
BAZ2B Q9UIF8 1/20 0.37
PDGFRA P16234 1/20 0.36
MAPK8 P45983 1/20 0.36
CDK5 Q00535 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
DGAT1 O75907 1/20 0.35
BRD4 O60885 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
MAPT P10636 1/20 0.35
KMT2A Q03164 1/20 0.35
CHRNB2 P17787 1/20 0.34
CHRNA3 P32297 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4487868 0.88 SLC2A1 (0.45) SLC2A1BRD4MEN1ALDH1A1MAPT
SCHEMBL4464652 0.88 SLC2A1 (0.47) SLC2A1PDGFRAMAPK8
SCHEMBL4487292 0.86 SLC2A1 (0.44) SLC2A1
SCHEMBL4484308 0.85 SLC2A1 (0.48) SLC2A1MEN1MAPTKMT2A
SCHEMBL4472787 0.85 SLC2A1 (0.58) SLC2A1DGAT1
SCHEMBL4479169 0.85 SLC2A1 (0.43) SLC2A1ALDH1A1
SCHEMBL13754687 0.84 HPGDS (0.43) SLC2A1HPGDSDHODHLDHABAZ2B
SCHEMBL4488013 0.84 SLC2A1 (0.45) SLC2A1DHODHBRD4POLBKMT2A
SCHEMBL4486512 0.84 SLC2A1 (0.47) SLC2A1DHODH
SCHEMBL9262450 0.82 PDGFRA (0.47) SLC2A1PDGFRAMAPK8CDK5CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-7579353-B2 Pyridinone derivatives against malaria GLAXO GROUP LIMITED (GB) 2009-08-25 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
US-20080287461-A1 Pyridinone Derivatives Against Malaria GLAXO GROUP LIMITED (GB) 2008-11-20 US disclosed
EP-1858876-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2007-11-28 EP disclosed
WO-2006094799-A2 PYRIDINONE DERIVATIVES AGAINST MALARIA GLAXO GROUP LIMITED (GB) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287461-A1 Pyridinone Derivatives Against Malaria G6PD, PNPO, PLPBP SLC2A1 2278/4885HPGDS 544/4885DHODH 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.